Association of aberrant DNA methylation with clinicopathological features in breast cancer

  • Authors:
    • Aggeliki Tserga
    • Nicolaos V. Michalopoulos
    • Georgia Levidou
    • Penelope Korkolopoulou
    • George Zografos
    • Efstratios Patsouris
    • Angelica A. Saetta
  • View Affiliations

  • Published online on: December 5, 2011     https://doi.org/10.3892/or.2011.1576
  • Pages: 1630-1638
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant DNA methylation is responsible for the epigenetic silencing of genes associated with tumourigenesis and progression of cancer. In this study, we assessed the methylation status of eight genes in 49 snap-frozen primary breast tumours. Epigenetic alterations of 8 genes were analysed with methylation-specific polymerase chain reaction (MS-PCR) (DCR1, DAPK1, RASSF1A and DCR2) or methylation-sensitive high-resolution melting analysis (MS-HRM) (APC, MGMT, GSTP1 and PTEN). MS-HRM performance was validated by bisulfite pyrosequencing regarding the methylation levels of MGMT. Promoter methylation was observed in APC 54.34%, 40.4% DCR1, 37.5% DAPK1, 33.3% RASSF1A, 22.44% MGMT, 16.6% GSTP1, 6% PTEN and 0% DCR2 promoters, respectively. Interestingly, 37 out of 49 cases (75.5%) displayed aberrant promoter methylation in at least one gene. An association of MGMT promoter methylation with age and tumour grade was recorded. Moreover, a correlation with advanced T-category was elicited for GSTP1, RASSF1 and DAPK1 promoter methylation. Finally, concurrent methylation of several genes showed a marginal statistical relationship with N-category. We conclude that APC, DCR1, DAPK1 and RASSF1A promoter methylation represents a common event in breast cancer tumourigenesis. Our results suggest that GSTP1, RASSF1, DAPK1 and MGMT may be implicated in the acquisition of a more aggressive phenotype in breast cancer.

Related Articles

Journal Cover

May 2012
Volume 27 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tserga A, Michalopoulos NV, Levidou G, Korkolopoulou P, Zografos G, Patsouris E and Saetta AA: Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep 27: 1630-1638, 2012
APA
Tserga, A., Michalopoulos, N.V., Levidou, G., Korkolopoulou, P., Zografos, G., Patsouris, E., & Saetta, A.A. (2012). Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncology Reports, 27, 1630-1638. https://doi.org/10.3892/or.2011.1576
MLA
Tserga, A., Michalopoulos, N. V., Levidou, G., Korkolopoulou, P., Zografos, G., Patsouris, E., Saetta, A. A."Association of aberrant DNA methylation with clinicopathological features in breast cancer". Oncology Reports 27.5 (2012): 1630-1638.
Chicago
Tserga, A., Michalopoulos, N. V., Levidou, G., Korkolopoulou, P., Zografos, G., Patsouris, E., Saetta, A. A."Association of aberrant DNA methylation with clinicopathological features in breast cancer". Oncology Reports 27, no. 5 (2012): 1630-1638. https://doi.org/10.3892/or.2011.1576